14 Result(s)
within
Anna M. Blom
Immunology
-
Article
Open AccessIntracellular cartilage oligomeric matrix protein augments breast cancer resistance to chemotherapy
Chemotherapy persists as the primary intervention for breast cancer, with chemoresistance posing the principal obstacle to successful treatment. Herein, we show that cartilage oligomeric matrix protein (COMP) ...
-
Article
Open AccessThe prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma
Cartilage oligomeric matrix protein (COMP) is a novel regulator of the tumor microenvironment. Studies in colon cancer and pancreatobiliary adenocarcinoma have revealed COMP expression to be associated with de...
-
Article
Open AccessTumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas
The complement inhibitor CSMD1 acts as a tumor suppressor in various types of solid cancers. Despite its high level of expression in the brain, its function in gliomas, malignant brain tumors originating from ...
-
Article
Open AccessCorrection: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
-
Article
Open AccessSushi domain-containing protein 4 binds to epithelial growth factor receptor and initiates autophagy in an EGFR phosphorylation independent manner
Sushi domain-containing protein 4 (SUSD4) is a recently discovered protein with unknown cellular functions. We previously revealed that SUSD4 can act as complement inhibitor and as a potential tumor suppressor.
-
Article
Open AccessComplement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
Human CUB and Sushi multiple domains 1 (CSMD1) is a large membrane-bound tumor suppressor in breast cancer. The current study aimed to elucidate the molecular mechanism underlying the effect of CSMD1 in highl...
-
Article
‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development
Therapeutic innovations of potentially great clinical impact should embrace the overarching values of research accountability, data transparency and validation through the scientific peer-review process.
-
Article
Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessTesting the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis
Autoantibodies termed C3-nephritic factor (C3NeF), which stabilize convertases of the alternative complement pathway, often stimulate autoinflammatory diseases. However, knowledge about analogous autoantibodie...
-
Article
Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence
Tumor cells often evade killing by the complement system by overexpressing membrane-bound complement inhibitors. However, production of soluble complement inhibitors in cells other than hepatocytes was rarely ...
-
Protocol
Purification and Functional Characterization of Factor I
Factor I (FI) is a soluble, 88 kDa glycoprotein present in plasma at a concentration of approximately 35 mg/L. FI inhibits all complement pathways as it degrades activated C4b and C3b when these are bound to a...
-
Protocol
Purification and Functional Characterization of C4b-Binding Protein (C4BP)
C4b-binding protein (C4BP) is a soluble, 570 kDa large glycoprotein, present in plasma at a concentration of approximately 200 mg/L. C4BP is the main inhibitor of the classical and lectin pathways of complemen...
-
Article
Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack
The complement system can be specifically targeted to tumor cells due to molecular changes on their surfaces that are recognized by complement directly or via naturally occurring antibodies. However, tumor cel...
-
Chapter and Conference Paper
Viral Heparin-Binding Complement Inhibitors – A Recurring Theme
